Annual FCF
$178.75 M
+$39.27 M+28.15%
December 31, 2024
Summary
- As of March 12, 2025, PCRX annual free cash flow is $178.75 million, with the most recent change of +$39.27 million (+28.15%) on December 31, 2024.
- During the last 3 years, PCRX annual FCF has risen by +$98.90 million (+123.86%).
- PCRX annual FCF is now at all-time high.
Performance
PCRX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
$31.01 M
-$18.81 M-37.76%
December 31, 2024
Summary
- As of March 12, 2025, PCRX quarterly free cash flow is $31.01 million, with the most recent change of -$18.81 million (-37.76%) on December 31, 2024.
- Over the past year, PCRX quarterly FCF has stayed the same.
- PCRX quarterly FCF is now -39.95% below its all-time high of $51.65 million, reached on June 30, 2024.
Performance
PCRX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
$178.75 M
-$14.77 M-7.63%
December 31, 2024
Summary
- As of March 12, 2025, PCRX TTM free cash flow is $178.75 million, with the most recent change of -$14.77 million (-7.63%) on December 31, 2024.
- Over the past year, PCRX TTM FCF has stayed the same.
- PCRX TTM FCF is now -7.63% below its all-time high of $193.53 million, reached on September 30, 2024.
Performance
PCRX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
PCRX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +28.1% | 0.0% | 0.0% |
| 3 y3 years | +123.9% | +34.2% | +72.0% |
| 5 y5 years | +196.1% | +34.2% | +72.0% |
PCRX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +123.9% | -40.0% | +146.9% | -7.6% | +123.9% |
| 5 y | 5-year | at high | +355.6% | -40.0% | +226.4% | -7.6% | +1262.1% |
| alltime | all time | at high | +302.2% | -40.0% | +219.7% | -7.6% | +302.2% |
Pacira BioSciences Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $178.75 M(+28.1%) | $31.01 M(-37.8%) | $178.75 M(-7.6%) |
| Sep 2024 | - | $49.83 M(-3.5%) | $193.53 M(+4.8%) |
| Jun 2024 | - | $51.65 M(+11.6%) | $184.74 M(+6.7%) |
| Mar 2024 | - | $46.27 M(+1.0%) | $173.19 M(+24.2%) |
| Dec 2023 | $139.49 M(+21.1%) | $45.79 M(+11.6%) | $139.49 M(+7.1%) |
| Sep 2023 | - | $41.04 M(+2.4%) | $130.25 M(+2.8%) |
| Jun 2023 | - | $40.09 M(+219.2%) | $126.68 M(+21.0%) |
| Mar 2023 | - | $12.56 M(-65.6%) | $104.65 M(-9.2%) |
| Dec 2022 | $115.20 M(+44.3%) | $36.55 M(-2.5%) | $115.20 M(+24.3%) |
| Sep 2022 | - | $37.47 M(+107.4%) | $92.70 M(-9.5%) |
| Jun 2022 | - | $18.07 M(-21.8%) | $102.44 M(-1.5%) |
| Mar 2022 | - | $23.11 M(+64.5%) | $103.95 M(+30.2%) |
| Dec 2021 | $79.85 M(+103.5%) | $14.05 M(-70.2%) | $79.85 M(-18.6%) |
| Sep 2021 | - | $47.21 M(+141.1%) | $98.06 M(+18.3%) |
| Jun 2021 | - | $19.58 M(-2074.1%) | $82.87 M(+113.8%) |
| Mar 2021 | - | -$992.00 K(-103.1%) | $38.76 M(-1.2%) |
| Dec 2020 | $39.23 M(-35.0%) | $32.26 M(+0.8%) | $39.23 M(+38.2%) |
| Sep 2020 | - | $32.02 M(-230.5%) | $28.38 M(+116.3%) |
| Jun 2020 | - | -$24.53 M(+4653.9%) | $13.12 M(-77.5%) |
| Mar 2020 | - | -$516.00 K(-102.4%) | $58.36 M(-3.3%) |
| Dec 2019 | $60.36 M(+75.7%) | $21.41 M(+27.7%) | $60.36 M(+4.2%) |
| Sep 2019 | - | $16.76 M(-19.1%) | $57.93 M(+8.6%) |
| Jun 2019 | - | $20.71 M(+1298.4%) | $53.34 M(+22.0%) |
| Mar 2019 | - | $1.48 M(-92.2%) | $43.71 M(+27.2%) |
| Dec 2018 | $34.36 M(-2419.8%) | $18.98 M(+55.9%) | $34.36 M(+26.2%) |
| Sep 2018 | - | $12.18 M(+9.9%) | $27.23 M(+298.7%) |
| Jun 2018 | - | $11.08 M(-240.7%) | $6.83 M(-218.9%) |
| Mar 2018 | - | -$7.87 M(-166.4%) | -$5.74 M(+287.8%) |
| Dec 2017 | -$1.48 M | $11.86 M(-244.1%) | -$1.48 M(+70.4%) |
| Sep 2017 | - | -$8.23 M(+448.8%) | -$869.00 K(-105.7%) |
| Jun 2017 | - | -$1.50 M(-58.5%) | $15.14 M(-1.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2017 | - | -$3.61 M(-129.0%) | $15.31 M(+75.1%) |
| Dec 2016 | $8.74 M(-171.2%) | $12.47 M(+60.3%) | $8.74 M(+108.8%) |
| Sep 2016 | - | $7.78 M(-686.1%) | $4.19 M(-140.4%) |
| Jun 2016 | - | -$1.33 M(-87.0%) | -$10.38 M(-24.3%) |
| Mar 2016 | - | -$10.17 M(-228.6%) | -$13.70 M(+11.7%) |
| Dec 2015 | -$12.27 M(-442.8%) | $7.91 M(-216.6%) | -$12.27 M(-14.1%) |
| Sep 2015 | - | -$6.79 M(+45.8%) | -$14.29 M(+311.8%) |
| Jun 2015 | - | -$4.65 M(-46.8%) | -$3.47 M(-202.6%) |
| Mar 2015 | - | -$8.74 M(-248.2%) | $3.38 M(-5.6%) |
| Dec 2014 | $3.58 M(-106.4%) | $5.90 M(+46.4%) | $3.58 M(-129.8%) |
| Sep 2014 | - | $4.03 M(+83.6%) | -$12.03 M(-60.7%) |
| Jun 2014 | - | $2.19 M(-125.7%) | -$30.59 M(-36.1%) |
| Mar 2014 | - | -$8.54 M(-12.0%) | -$47.83 M(-14.6%) |
| Dec 2013 | -$56.01 M(-36.6%) | -$9.71 M(-33.2%) | -$56.01 M(-22.4%) |
| Sep 2013 | - | -$14.53 M(-3.4%) | -$72.22 M(-3.9%) |
| Jun 2013 | - | -$15.05 M(-10.0%) | -$75.12 M(-11.3%) |
| Mar 2013 | - | -$16.72 M(-35.5%) | -$84.66 M(-4.2%) |
| Dec 2012 | -$88.39 M(+137.8%) | -$25.91 M(+48.6%) | -$88.39 M(+21.8%) |
| Sep 2012 | - | -$17.43 M(-29.1%) | -$72.56 M(+11.2%) |
| Jun 2012 | - | -$24.59 M(+20.3%) | -$65.26 M(+23.6%) |
| Mar 2012 | - | -$20.45 M(+102.9%) | -$52.79 M(+42.0%) |
| Dec 2011 | -$37.17 M(+17.4%) | -$10.08 M(-0.6%) | -$37.17 M(+3.6%) |
| Sep 2011 | - | -$10.14 M(-16.4%) | -$35.88 M(+3.9%) |
| Jun 2011 | - | -$12.13 M(+151.6%) | -$34.55 M(+6.4%) |
| Mar 2011 | - | -$4.82 M(-45.2%) | -$32.46 M(+2.5%) |
| Dec 2010 | -$31.65 M(+20.1%) | -$8.79 M(-0.3%) | -$31.65 M(+38.4%) |
| Sep 2010 | - | -$8.81 M(-12.2%) | -$22.86 M(+62.7%) |
| Jun 2010 | - | -$10.04 M(+150.1%) | -$14.05 M(+250.1%) |
| Mar 2010 | - | -$4.01 M | -$4.01 M |
| Dec 2009 | -$26.35 M(-24.8%) | - | - |
| Dec 2008 | -$35.03 M | - | - |
FAQ
- What is Pacira BioSciences annual free cash flow?
- What is the all time high annual FCF for Pacira BioSciences?
- What is Pacira BioSciences annual FCF year-on-year change?
- What is Pacira BioSciences quarterly free cash flow?
- What is the all time high quarterly FCF for Pacira BioSciences?
- What is Pacira BioSciences quarterly FCF year-on-year change?
- What is Pacira BioSciences TTM free cash flow?
- What is the all time high TTM FCF for Pacira BioSciences?
- What is Pacira BioSciences TTM FCF year-on-year change?
What is Pacira BioSciences annual free cash flow?
The current annual FCF of PCRX is $178.75 M
What is the all time high annual FCF for Pacira BioSciences?
Pacira BioSciences all-time high annual free cash flow is $178.75 M
What is Pacira BioSciences annual FCF year-on-year change?
Over the past year, PCRX annual free cash flow has changed by +$39.27 M (+28.15%)
What is Pacira BioSciences quarterly free cash flow?
The current quarterly FCF of PCRX is $31.01 M
What is the all time high quarterly FCF for Pacira BioSciences?
Pacira BioSciences all-time high quarterly free cash flow is $51.65 M
What is Pacira BioSciences quarterly FCF year-on-year change?
Over the past year, PCRX quarterly free cash flow has changed by $0.00 (0.00%)
What is Pacira BioSciences TTM free cash flow?
The current TTM FCF of PCRX is $178.75 M
What is the all time high TTM FCF for Pacira BioSciences?
Pacira BioSciences all-time high TTM free cash flow is $193.53 M
What is Pacira BioSciences TTM FCF year-on-year change?
Over the past year, PCRX TTM free cash flow has changed by $0.00 (0.00%)